News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell N.V. (CRXL) Announces PER.C6(R) Licensing Agreement with Acambis (ACAM)



11/20/2007 4:05:33 PM

LEIDEN, NETHERLANDS--(Marketwire - November 20, 2007) - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and Acambis plc (London Stock Exchange: ACM) today announced the signing of a research license agreement for PER.C6®. The license agreement allows Acambis to use Crucell's PER.C6® technology for an undisclosed vaccine candidate. Financial details of the agreement were not disclosed.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES